2.24
Schlusskurs vom Vortag:
$2.10
Offen:
$2.13
24-Stunden-Volumen:
530.41K
Relative Volume:
0.60
Marktkapitalisierung:
$238.37M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-6.5882
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+6.16%
1M Leistung:
+9.80%
6M Leistung:
-55.73%
1J Leistung:
-50.33%
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MXCT
Maxcyte Inc
|
2.24 | 224.33M | 45.44M | -35.43M | -25.39M | -0.34 |
![]()
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-22 | Eingeleitet | Stephens | Overweight |
2023-11-29 | Eingeleitet | Craig Hallum | Buy |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-08-24 | Eingeleitet | BTIG Research | Buy |
2021-08-24 | Eingeleitet | Cowen | Outperform |
2021-08-24 | Eingeleitet | Stephens | Overweight |
2021-08-24 | Eingeleitet | Stifel | Buy |
2021-08-24 | Eingeleitet | Wedbush | Outperform |
2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Is MaxCyte Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional
What analysts say about MaxCyte Inc. stockExplosive earning power - Autocar Professional
What drives MaxCyte Inc. stock priceJaw-dropping returns - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastMarket-leading profit generation - jammulinksnews.com
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
How MaxCyte Inc. stock performs during market volatilityDaily Swing Candidates - Newser
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte shares trading for last time in London - Sharecast.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
MaxCyte shareholders approve equity plan expansion, AIM delisting By Investing.com - Investing.com UK
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing - Investing.com Australia
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - The Manila Times
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency - Nasdaq
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):